Periodic Reporting for period 1 - Reminova02 (Feasibility Study to Demonstrate Effectiveness and Efficiency of Enamel Remineralisation using Reminova's EAER (Electrically Accelerated Enhanced Remineralisation) Technology for Dental Applications)
Reporting period: 2016-05-01 to 2016-10-31
Treating caries on a global scale and the serious illnesses that result from untreated caries (which happens a lot because many people are very fearful of going to the dentist) costs over 300 billion euro's annually, sucking up over five percent of the global health budget.
Reminova can change this, with our painless reparative treatment known as EAER.
It reverses the effects of caries attack and repairs enamel.
Its an essentially painless process, and the repaired areas of the enamel are almost identical to natural enamel, as we use the same natural building block of tooth enamel, which are calcium and phosphate groups.
This treatment can be important in reducing overall dental costs, and reducing the impact of dental caries on society.
Having a painless treatment can increase dental attendance, as throughout most countries of Europe, around one in four of the population do not attend a dentist regularly or at all.
Our Feasibility Study objective was to analyse and evidence the commercial potential and opportunity that this treatment offers. In answering critical technical uncertainties we have been able to sharpen the commercial value proposition.
This will enable our Company to attract further investment and expedite commercial discussions.
Our Company has a number of activities underway which in 2017 will build on the findings of the Phase 1 Feasibility Study.
The work plan helped provide compelling analytical evidence to support our disruptive dental treatment to stop and repair enamel caries, painlessly and quickly using materials that are similar to enamel’s natural constituents.
From this analytical work we were able to see clearly what steps we needed to take to develop a 15-20 minute treatment product and this helped provide a more defined commercial value proposition.
We have summarized in this final report how we plan to go forward and how instrumental the Phase 1 funding has been for our Company development.
We have developed a more detailed and fully costed development plan based on the Feasibility Study findings and our other company work.
A Phase 2 H2020 application is in development and will be submitted in early 2017, and will make use of our detailed plan.
We have updated and strengthened our business plan to support our commercial activities. We have plans for further external investment in 2017 supporting our H2020 application.
We aim to complete two commercial deals with major collaborators and generate revenue from these activities in 2017, covering different applications of our EAER technology.
We showed that EAER can make a major impact on global oral health and disrupt the treatment of dental caries globally.
The approach can have a significant health and socio-economic impact, increasing health and well-being and reducing the overall costs of dental services.
The treatment can provide a new way to maintain tooth health over a lifetime.
A treatment without drills and anaesthetic injections can boost dental attendance, as well as making it easier to offer in developing countries due to the lower risk and less infrastructure required.